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Background: Various adipokines are reported to be associated with the development of heart failure (HF) through
insulin resistance and chronic inflammation. Omentin-1 is a novel adipokine and is associated with incident
coronary artery disease. However, it remains unclear whether serum omentin-1 levels are associated with cardiac
prognosis in patients with HF.
Methods: We measured serum omentin-1 levels at admission in 136 consecutive patients with HF, and 20 control
subjects without signs of significant heart disease. We prospectively followed patients with HF to endpoints of
cardiac death or re-hospitalization for worsening HF.
Results: Serum omentin-1 levels were markedly lower in HF patients with cardiac events compared with to without.
The patients who were in New York Heart Association (NYHA) functional class IV showed significantly lower serum
omentin-1 levels compared to those in class II and III, whereas serum omentin-1 levels did not correlate with serum
brain natriuretic peptide levels (r = 0.217, P = 0.011). We divided the HF patients into three groups based on the
tertiles of serum omentin-1 level (low T1, middle T2, and high T3). Multivariate Cox hazard analysis showed that the
lowest serum omentin-1 level (T1) was independently associated with cardiac events after adjustment for confounding
factors (hazard ratio 5.78, 95% confidence interval 1.20-12.79). We divided the HF patients into two groups according to
the median serum omentin-1 levels. Kaplan-Meier analysis revealed that the patients with low serum omentin-1 levels
had a higher risk of cardiac events compared with those with high serum omentin-1 levels (log-rank test p < 0.001).
Conclusion: Decreased serum omentin-1 levels were associated with a poor cardiac outcome in patients with HF.
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Heart failure (HF) remain a major cause of death worldwide
and has a poor prognosis despite advances in treatment [1].
Adipocytokines, such as tumor necrosis factor-alpha,
interleukin-6, and plasminogen activator inhibitor-1, play
a crucial role in the development of cardiovascular dis-
eases through insulin resistance and chronic inflamma-
tion [2-5]. Adipokines, such as adiponectin, are also
reported to have anti-inflammatory, anti-oxidant, and
anti-apoptotic properties, and are decreased in patients
with cardiovascular disease [6-9]. There has been a
move to clarify the causal relationship between various
adipokines and cardiovascular disease [10,11].* Correspondence: tewatana@med.id.yamagata-u.ac.jp
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unless otherwise stated.Omentin-1 is a novel adipokine whose serum levels
are decreased in obese individuals, and is associated with in-
sulin resistance [12-16]. Omentin-1 has been suggested to
play a beneficial role in preventing atherosclerosis [17,18],
however, it remains unclear whether serum omentin-1 levels
are associated with clinical outcome in patients with HF.
The purpose of this study was to clarify the impact of
serum omentin-1 levels on cardiac prognosis in patients
with HF.Methods
Study population
We enrolled 136 consecutive patients who were admitted
to the Yamagata University Hospital for treatment of wors-
ening HF, diagnosis and pathophysiological investigations,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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control subjects without signs of significant heart disease.
A diagnosis of HF was based on a history of dyspnea
and symptoms of exercise intolerance followed by pul-
monary congestion, pleural effusion, or left ventricular en-
largement by chest X-ray or echocardiography [19,20].
Control subjects were excluded if they had significant cor-
onary artery disease, systolic and diastolic dysfunction,
valvular heart disease, or myocardial hypertrophy on echo-
cardiography [21]. All patients gave written informed con-
sent prior to their participation, and the protocol was
approved by the institution’s Human Investigation Com-
mittee. The procedures were performed in accordance
with the Helsinki Declaration.
Measurement of serum omentin-1 and brain natriuretic
peptide levels
Blood samples were drawn at admission and centrifuged
at 2,500 g for 15 minutes at 4°C within 30 minutes of
collection. The serum was stored at −80°C until analysis.
Serum omentin-1 concentrations were measured with a
sandwich enzyme-linked immunosorbent assay (ELISA,
Immuno-Biological Laboratories CO., Ltd., Gunma, Japan),
according to the manufacturer’s instructions [22,23]. The
serum omentin-1 levels were measured in duplicate by an
investigator unaware of the associated patients’ characteris-
tics. Serum brain natriuretic peptide (BNP) concentrations
were measured using a commercially available specific
radio-immuno assay for human BNP (Shiono RIA BNP
assay kit, Shionogi & Co., Ltd., Tokyo, Japan) [24].
Endpoints and follow-up
The patients were prospectively followed for a median dur-
ation of 399 ± 378 days. The end points were cardiac death,
including death due to progressive HF, myocardial infarc-
tion, stroke and sudden cardiac death, and re-hospitalization
for worsening HF. Sudden cardiac death was defined as
death without definite premonitory symptoms or signs, and
was confirmed by the attending physician. Two cardiologists
who were blinded to the blood biomarker data reviewed the
medical records and conducted telephone interviews to sur-
vey the incidence of cardiovascular events.
Statistical analysis
Data are presented as the mean ± standard deviation
(SD). The Mann–Whitney U-test was used when the data
were not distributed normally. If the data were not distrib-
uted normally, they were presented as medians with an
interquartile range. The unpaired Student’s t-test and the
chi-square test were used for comparisons of continuous
and categorical variables, respectively. Comparison of data
among three groups was performed by the Kruskal-Wallis
test. Uni- and multivariate analyses with Cox proportional
hazard regression were used to determine significantpredictors of cardiovascular events. Cumulative overall
and event-free survival rates were computed using the
Kaplan-Meier method and were compared using the log-
rank test. We calculated the net reclassification improve-
ment (NRI) and the integrated discrimination improvement
(IDI) to measure the quantity of improvement for the cor-
rect reclassification and sensitivity according to the addition
of serum omentin-1 levels to the prediction model [25].
NRI and IDI are new statistical measures to assess and
quantify the improvement in risk prediction offered by
a new marker. A P value < 0.05 was considered statisti-
cally significant. All statistical analyses were performed
with a standard statistical program package (JMP ver-
sion 10; SAS Institute, Cary, North Carolina, USA), and
the R-3.0.2 with additional packages (Rcmdr, Epi,
pROC, and PredictABEL).Results
Comparison between patients with and without
heart failure
The patients with HF had a lower BMI and left ventricu-
lar ejection fraction, and lower serum total cholesterol,
triglyceride levels, and higher serum BNP levels com-
pared with control subjects (Table 1).Comparison between HF patients with and without
cardiac events
There were 59 cardiac events including 17 deaths and
32 re-hospitalizations in patients with HF during the
follow-up period (Table 2). The patients who experi-
enced cardiac events were in a more severe New York
Heart Association (NYHA) functional class, and had a
lower estimated glomerular filtration rate, lower left
ventricular ejection fraction, higher left ventricular
end-diastolic diameter, and higher serum BNP levels com-
pared with those who did not. Moreover, patients with
cardiac events showed markedly lower serum omentin-1
levels compared with those without (Figure 1). There were
no significant differences in etiologies of HF between pa-
tients with and without cardiac events (Table 2).Serum omentin-1 levels and HF severity
The patients who were in NYHA functional class IV
showed significantly lower serum omentin-1 levels com-
pared to those in class II and III (P = 0.029 vs. class II and
P = 0.041 vs. class III, Figure 2A). On the other hand,
serum omentin-1 levels were not significantly different be-
tween the patients who were in NYHA functional class II
and III (P = 0.582). Furthermore, there was no relationship
between the serum omentin-1 levels and the serum BNP
levels (r = 0.217, Figure 2B).







Age, years 65 ± 16 72 ± 12 0.034




Etiology, n (%) -
Dilated cardiomyopathy - 29 (21)
Valvular heart disease - 38 (28)
Ischemic heart disease - 30 (22)
Hypertensive heart disease - 14 (10)
Hypertrophic cardiomyopathy - 9 (7)
Others - 16 (12)
Presentation profile
Systolic pressure, mmHg 119 ± 22 117 ± 18 0.772
Diastolic pressure, mmHg 77 ± 10 74 ± 10 0.209
Body mass index, kg/m2 23.3 ± 3.4 21.7 ± 3.9 0.049
eGFR, ml/min/1.73m2 70 ± 24 62 ± 26 0.197
Blood biomarkers
Albumin, g/dl 3.8 ± 0.5 3.5 ± 0.6 0.091
Total cholesterol, mg/dl 185 ± 34 166 ± 39 0.042
Triglyceride, mg/dl 143 ± 96 91 ± 47 <0.001
LDLc, mg/dl 111 ± 28 100 ± 37 0.213
HDLc, mg/dl 52 ± 15 53 ± 23 0.831





BNP, pg/ml (IQR) 82 (50–152) 484 (215–1251) <0.001
Omentin-1, ng/ml (IQR) 494 (351–630) 305 (35–473) 0.035
Echocardiographic data
LV end-diastolic diameter, mm 53 ± 8 55 ± 11 0.438
LV ejection fraction, % 65 ± 9 50 ± 18 <0.001
Medications, n (%)
ACE inhibitors and/or ARBs 15 (75) 102 (75) 0.999
β blockers 15 (75) 103 (76) 0.943
Statins 10 (50) 51 (38) 0.321
Ca channel blockers 5 (25) 37 (27) 0.778
Data are presented as mean±SD or % unless otherwise indicated; ACE,
angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain
natriuretic peptide; BUN, Blood urea nitrogen; eGFR, estimated glomerular
filtration rate; HDLc, high density lipoprotein cholesterol; hsCRP, high-sensitivity
C-reactive protein; IQR, interquartile range; LDLc, low density lipoprotein
cholesterol; LV, left ventricular; NYHA, New York Heart Association.








Age, years 71 ± 10 72 ± 14 0.687
Male, n (%) 40 (52) 36 (61) 0.480
NYHA functional class, II/III/IV 49/21/6 22/25/13 0.005
Etiology, n (%) 0.348
Dilated cardiomyopathy 12 (16) 17 (29) -
Valvular heart disease 24 (31) 14 (24) -
Ischemic heart disease 17 (22) 13 (22) -
Hypertensive heart disease 8 (10) 6 (10) -
Hypertrophic cardiomyopathy 6 (8) 3 (5) -
Others 10 (13) 6 (10) -
Presentation profile
Systolic pressure, mmHg 116 ± 18 118 ± 19 0.598
Diastolic pressure, mmHg 73 ± 9 74 ± 11 0.780
Body mass index, kg/m2 22.0 ± 4.4 21.4 ± 3.3 0.413
eGFR, ml/min/1.73m2 66 ± 27 57 ± 24 0.046
Blood biomarkers
Albumin, g/dl 3.5 ± 0.6 3.5 ± 0.6 0.539
Total cholesterol, mg/dl 169 ± 37 163 ± 42 0.398
Triglyceride, mg/dl 97 ± 48 84 ± 45 0.132
LDLc, mg/dl 101 ± 37 99 ± 37 0.731
HDLc, mg/dl 55 ± 29 52 ± 12 0.437





BNP, pg/ml (IQR) 453 (248–1249) 512 (169–1255) 0.049
Omentin-1, ng/ml (IQR) 479 (323–661) 139 (57–402) <0.001
Echocardiographic data
LV end-diastolic diameter, mm 53 ± 10 57 ± 10 0.011
LV ejection fraction, % 56 ± 17 45 ± 16 <0.001
Medications, n (%)
ACE inhibitors and/or ARBs 54 (70) 48 (81) 0.134
β blockers 52 (68) 51 (86) 0.029
Statins 23 (30) 28 (47) 0.460
Ca channel blockers 29 (3) 8 (14) 0.964
Data are presented as mean±SD or % unless otherwise indicated; ACE,
angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain
natriuretic peptide; BUN, Blood urea nitrogen; eGFR, estimated glomerular
filtration rate; HDLc, high density lipoprotein cholesterol; hsCRP, high-sensitivity
C-reactive protein; IQR, interquartile range; LDLc, low density lipoprotein
cholesterol; LV, left ventricular; NYHA, New York Heart Association.
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cardiac events
We divided patients with HF into three groups according
to the tertiles of serum omentin-1 levels. Multivariate Cox
hazard analysis showed that the lowest serum omentin-1
levels (T1) were independently associated with cardiac
events after adjustment for age, gender, NYHA functionalclass, left ventricular ejection fraction, and serum brain
natriuretic peptide levels (hazard ratio 5.65, 95% confi-
dence interval 2.61-12.20; Figure 3, Table 3). We divided
the patients into two groups according to the median
serum omentin-1 levels. Kaplan-Meier analysis revealed
that the patients with low serum omentin-1 levels had a
Figure 1 Comparisons of serum omentin-1 levels between control subjects and HF patients with or without cardiac events. HF patients
with cardiac events showed markedly lower serum omentin-1 levels compared with those without (p < 0.001). HF, heart failure.
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serum omentin-1 levels (log-rank test p < 0.001, Figure 4).
Net reclassification improvement and integrated
discrimination improvement
To measure the quantity of improvement for the correct
reclassification and sensitivity according to the addition
of serum omentin-1 levels to the prediction model, we
calculated the NRI and the IDI. The inclusion of serum
omentin-1 levels in the prediction model (includes age,
gender, NYHA functional class, left ventricular ejection
fraction, and serum BNP levels) for the prediction of
cardiac events, improved the NRI and IDI values, sug-
gesting effective reclassification and discrimination
(Table 4).
Discussion
The present study demonstrated that decreased serum
omentin-1 levels predicted cardiac events in patients withFigure 2 Serum omentin-1 levels and heart failure severity. A. The pat
serum omentin-1 levels compared to those in class II and III (*P = 0.029 vs.
II = 71, III = 46, IV = 19) B. The association between serum omentin-1 levels
omentin-1 levels and the serum BNP levels (r = 0.217). BNP, brain natriureticHF. Serum omentin-1 level appears to be a novel prognos-
tic marker for the risk stratification of patients with HF.
Various types of adipocytokines are reported to be a pre-
dictor of unfavorable cardiac outcomes in patients with
HF [26]. In addition to their roles as predictors of cardiac
outcome, a variety of adipocytokines have been associated
with the development of HF through insulin resistance
and chronic inflammation [14,27-29]. Serum adiponectin
levels are reported to be correlated with BNP levels, and
are associated with HF severity and unfavorable outcomes
in patients with HF [30,31]. Adiponectin has been sug-
gested to play a role in the prevention of cardiovascular
diseases via its anti-inflammatory, anti-oxidant, and anti-
apoptotic properties [6-9]. Recently, reports have shown
several adipokines to have beneficial effects on cardiovas-
cular diseases [32-34]. However, the precise role of these
adipokines remains unclear.
Omentin-1 is a 38 kDa novel adipokine identified in 2004
from visceral adipose tissue [12,13]. Shibata et al. reportedients who were in NYHA functional class IV showed significantly lower
class II and #P = 0.041 vs. class III, Figure 2A). (The number of patients;
and serum BNP levels. There was no relationship between the serum
peptide; NYHA, New York Heart Association.
Figure 3 Hazard ratio of the tertiles of omentin-1 levels for
cardiac events after adjustment of age, gender, body mass
index, NYHA functional class, left ventricular ejection fraction,
serum triglycerides, serum HDLc levels, and serum BNP levels.
BNP, brain natriuretic peptide; HDLc, high density lipoprotein
cholesterol; NYHA, New York Heart Association.
Figure 4 Kaplan-Meier analysis. The patients with low serum
omentin-1 levels had a higher risk of cardiac events compared to
those with high serum omentin-1 levels (log-rank test p < 0.001).
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lence of coronary artery disease [18]. Yang et al. reported
that omentin-1 enhances insulin-stimulated glucose uptake
in human adipocytes and may regulate insulin sensitivity
[13]. Yamawaki et al. reported that omentin-1 modulates
vascular function and attenuates cyclooxygenase-2 expres-
sion and c-jun N-terminal kinase (JNK) activation in
cytokine-stimulated endothelial cells [35,36]. These studies
all suggest that omentin-1 may improve insulin resistance
and suppress vascular inflammation. Interestingly, Pan et al.
suggested that omentin-1 expression and production areTable 3 Univariate and multivariate analyses for
cardiac events
Univariate Analysis Multivariate Analysis







T3 1 Reference Reference 1 Reference Reference
T2 5.56 2.85-10.87 <0.001 4.15 2.03-8.47 <0.001
T1 6.29 1.30-
13.06
<0.001 5.65 2.61-12.20 <0.001
*Adjusted HR after adjustment for age, gender, body mass index, NYHA
functional class, left ventricular ejection fraction, serum triglycerides, serum
HDLc levels, and serum BNP levels.
BNP, brain natriuretic peptide; CI, confidence interval; HDLc, high density
lipoprotein cholesterol; HR, hazard ratio; NYHA, New York Heart Association;
SD, standard deviation.decreased with elevated inflammatory adipokines, such as
tumor necrosis factor-alpha and interleukin-6, in patients
with impaired glucose intolerance and newly diagnosed
type 2 diabetes mellitus [37].
Unlike to adiponectin, serum omentin-1 was reported to
decrease with chronic inflammation and oxidative stress
in patients with HF. The bioactivity of omentin-1 appears
multifaceted and remains to be fully defined. The present
study showed no correlation between serum omentin-1
and BNP levels unlike adiponectin [30], suggesting that
these markers indicate different features of the patho-
physiological process of HF. Serum omentin-1 levels may
represent a promising biomarker for cardiac prognosis, ir-
respective of serum BNP levels. The inclusion of serum
omentin-1 levels in the prediction model (includes age,
gender, NYHA functional class, left ventricular ejection
fraction, and serum BNP levels) for the prediction of car-
diac events, improved the NRI and IDI values, suggesting
effective reclassification and discrimination.
The present study has certain limitations. Firstly, the
sample size was relatively small and it was a single center
study. Nonetheless, there was a significant relationship be-
tween serum omentin-1 levels and cardiac events. In
addition, the inclusion of serum omentin-1 levels in theTable 4 Statistics for model fit and improvement with
addition of serum omentin-1 level predicted on the






NRI (95% CI) Reference 0.375 (0.129-0.620) 0.002
IDI (95% CI) Reference 0.149 (0.087-0.211) <0.001
Prediction model includes age, gender, NYHA functional class, left ventricular
ejection fraction, and serum BNP levels.
BNP, brain natriuretic peptide; CI, confidence interval; IDI, integrated
discrimination improvement; NRI, net reclassification improvement; NYHA,
New York Heart Association.
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serum BNP levels, for the prediction of cardiac events, im-
proved the NRI and IDI values. Secondly, there were no
data for other adipocytokines. Further study is needed to
clarify the association between serum omentin-1 and
other adipocytokines in a large HF population.
In conclusion, decreased serum omentin-1 levels were as-
sociated with cardiac events in patients with HF, irrespect-
ive of serum BNP levels. Serum omentin-1 level appears to
represent a novel prognostic marker for the risk stratifica-
tion of patients with HF.
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